Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04925570
Other study ID # 58725
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 14, 2022
Est. completion date August 17, 2023

Study information

Verified date August 2023
Source Woebot Health
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to validate W-SUDs as a digitally-delivered substance use disorder program through a fully-powered randomized control trial that will test the comparative efficacy of the mobile-app based substance use disorder program (W-SUDs) to reduce substance use relative to a psychoeducation control condition, which has no cognitive behavioral therapy and the content is not delivered through a conversational user interface.


Description:

Phase II will evaluate the efficacy of W-SUDs in a large scale RCT relative to a psychoeducation control condition. Primary outcomes will be measures of the quantity and frequency of substance use including number of substance use occasions, heavy drinking days (if applicable) and percent of days abstinent. Additionally, Phase II will evaluate whether W-SUDs results in a greater reduction in substance-related problems compared to a psychoeducation control group and explore if engagement with W-SUDs, relative to psychoeducation control, 1. improves symptoms of depression and anxiety; 2. improves work productivity (i.e. reduce presenteeism/absenteeism); 3. reduces cravings; 4. improves situational confidence to resist substance use.


Recruitment information / eligibility

Status Completed
Enrollment 258
Est. completion date August 17, 2023
Est. primary completion date August 17, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Have a smartphone 2. Endorse a substance use concern 3. Be between 18 and 65 years of age 4. Be available and committed to engage with the Woebot app 5. Be literate in English. (This is required for inclusion because all materials will be in English). Exclusion Criteria: 1. Pregnancy (as W-SUDs will not be specifically developed to address the unique needs of this population) 2. Suicide attempt within the past year (12 months) 3. Symptoms of severe drug/alcohol history: History of delirium tremens; Experiencing hypertension, drenching sweats, seizures or confusion after stopping alcohol or drugs; Liver trouble (cirrhosis or hepatitis); Convulsions or GI bleeding due to drug/alcohol use 4. Opioid overdose within the past year (12 months) 5. Opioid misuse without medication-assisted treatment 6. Not residing in the U.S. 7. Previous Woebot use

Study Design


Intervention

Device:
W-SUDs
Woebot (W-SUDs) is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
Other:
Digitally-delivered Psychoeducation
A form of psychoeducation for those seeking treatment for their alcohol and/or substance use concern. Psychoeducation is commonly provided for those with substance use. Psychoeducation in substance use is intended to increase the users' knowledge of their substances of use, and effects on the body, behaviors, and consequences. The recipient of psychoeducation is expected to increase their own awareness of their substance use and ideally incorporate this newfound knowledge when making changes to their substance use. The information provided in this group are from factsheets found on NIAAA, NIDA, and CDC web pages.

Locations

Country Name City State
United States Stanford University Palo Alto California

Sponsors (2)

Lead Sponsor Collaborator
Woebot Health Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of substance use occasions Number of substance use occasions in the past 30 days Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks
Secondary Drug Abuse Screening Test (DAST-10) Measure of drug abuse related consequences. The DAST-10 is a brief, 10-item self-report measure that assesses consequences related to drug abuse, excluding alcohol and tobacco. The range is 0-10, where higher scores indicate greater severity. Adapted from past 12 months to past 30 days. Change from Baseline to Post-treatment at 8 weeks
Secondary Working Alliance Inventory (WAI-SR) Measure of working alliance. A measure of therapeutic alliance that assesses three key aspects of the therapeutic alliance: (a) agreement on the tasks of therapy, (b) agreement on the goals of therapy and (c) development of an affective bond. Scores range from 5-20, with higher scores indicating greater alliance. The present study utilized the validated 12-item Short-Revised version (WAI-SR) with minor changes to language, replacing "therapist" with "Woebot". Change from Mid-treatment at 4 weeks to Post-treatment at 8 weeks
Secondary Stanford Presenteeism Scale (SPS-6) Measure of workforce productivity. A six item measure derived from a 34 item measure of workforce productivity impacted by health status. The 6-item scale has excellent psychometric properties and has been validated. Change from Baseline to Post-treatment at 8 weeks
Secondary Thoughts About Abstinence (TAA) Measure of thoughts about abstinence. Modified for alcohol and substances. 5-item questionnaire assessing desire to quit, expected success at quitting, expected difficulty of quitting, and confidence in ability to quit measured on 10-point Likert scales. The fifth item assesses partcipants' abstinence goal. Change from Baseline to Post-treatment at 8 weeks
Secondary Usage Rating Profile - Intervention (URPI)-Acceptability Measure of acceptability. A 6-item subscale that inquires about intervention acceptability. Responses range from 1 = "strongly disagree" to 6 = "strongly agree". Scores are averages, with greater scores indicating greater intervention acceptability. Post-treatment (8 weeks from Baseline)
Secondary Usage Rating Profile - Intervention (URPI)-Feasibility Measure of feasibility. A 6-item subscale that inquires about factors that impact treatment usage (i.e., intervention quality). Responses range from 1 = "strongly disagree" to 6 = "strongly agree". Scores are averages, with greater scores indicating greater intervention feasibility. Post-treatment (8 weeks from Baseline)
Secondary Client Satisfaction Questionnaire (CSQ) Measure of satisfaction. An 8-item measure used to assess client's satisfaction with treatment on a 4-point scale. Example questions include, "How would you rate the quality of service you received"? and "Did you get the kind of service you wanted?" Total sums range from 8-32, with high scores indicating greater satisfaction with the W-SUDs mobile application. Post-treatment (8 weeks from Baseline)
Secondary Short Inventory of Problems- Alcohol and Drugs (SIP-AD) Measure of substance use problems. The SIP-AD assesses substance use problems in the past 30 days. The scored variables, total scores and 15-item mean, summarize consequences of alcohol and drug use. Scores range from 0-45, where greater scores indicate greater substance use problems. Change from Baseline to Mid-Treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks
Secondary Patient Health Questionnaire (PHQ-8) Measure of depression. An 8-item self-report questionnaire that assesses the frequency and severity of depression symptoms. Total scores range from 0 to 24 where higher scores indicate greater levels of depression. Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks
Secondary Generalized Anxiety Disorder (GAD-7) Measure of anxiety. A 7-item brief self-report measure used to assess the frequency and severity of anxious thoughts and behaviors over the past 2 weeks. Total score between 0-21, where higher scores indicate greater levels of anxiety. Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks
Secondary Brief Situational Confidence Questionnaire (BSCQ) Measure of self-confidence. The 8-item BSCQ is a state dependent measure that assesses self-confidence to resist the urge to drink heavily or use drugs in a variety of situations. Each of the 8 scale situations consists of a 100-mm line, anchored by 0% ("not at all confident") and 100% ("totally confident") where clients are asked to indicate confidence on a scale from 0% to 100%. Higher scores are associated with greater confidence. Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks
Secondary Craving Ratings Measure of craving. A self-reported rating of craving intensity. Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks
Secondary Quick Drinking Screen (QDS) Measure of alcohol use. A self-report measure used to assess alcohol use including quantity consumed, frequency of drinking, and binge incidences. Change from Baseline to Mid-treatment at 4 weeks; Change from Baseline to Post-treatment at 8 weeks; Change from Baseline to Follow-up at 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05660434 - Using Aromatherapy in Substance Use Disorder N/A
Active, not recruiting NCT05338268 - Substance Use and Loneliness N/A
Completed NCT03954184 - E-health Implementation (Iowa) N/A
Completed NCT04098614 - Barriers to Substance Use Disorder Recovery N/A
Completed NCT03590106 - Cardiac Surgery Peer Recovery Support Program N/A
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Recruiting NCT06273228 - Parenting Young Children in Pediatrics N/A
Recruiting NCT05327504 - Written Exposure Therapy for Veterans With SUD and PTSD N/A
Terminated NCT03517111 - The Impact of a Parenting Intervention on Latino Youth Health Behaviors N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04401215 - Technologically-Augmented Referrals to Mitigate Addiction Consequences N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06187701 - Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients N/A
Recruiting NCT04296604 - Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations N/A
Active, not recruiting NCT02382042 - Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans N/A
Completed NCT01237366 - Study Targeting Affect Regulation Phase 1/Phase 2
Terminated NCT01356667 - Drum-Assisted Therapy for Native Americans N/A
Completed NCT00708890 - Twelve Step Based Self-help Groups for Substance Related Disorders N/A
Active, not recruiting NCT04048850 - Zepatier in Patients With Substance Use
Recruiting NCT05976646 - Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion Phase 1/Phase 2